Redhill Biophrma ADR (RDHL)

$1.34 -0.11 (-7.59%)
Market Cap 3.33M
Revenue (ttm) 8.04M
Net Income (ttm) -8.27M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -102.86%
Debt to Equity Ratio 0.00
Volume 75,500
Avg Vol 610,642
Day's Range N/A - N/A
Shares Out 2.30M
Stochastic %K 67%
Beta 4.18
Analysts Strong Buy
Price Target $40.00

Company Profile

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear ra...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 972 3 541 3131
Fax: 972 3 541 3144
Address:
21 Ha’arba’a Street, Tel Aviv, Israel
therealchorris
therealchorris Aug. 20 at 3:23 PM
$RDHL Looks sh’t…
0 · Reply
musti34
musti34 Aug. 20 at 1:14 PM
$RDHL RedHill Biopharma Awarded $1.8 Million in Legal Costs and Expenses by New York Supreme Court in Addition to its Prior $8.25 Million Summary Judgment Win https://www.redhillbio.com/news/news-details/2025/RedHill-Biopharma-Awarded-1-8-Million-in-Legal-Costs-and-Expenses-by-New-York-Supreme-Court-in-Addition-to-its-Prior-8-25-Million-Summary-Judgment-Win/default.aspx
0 · Reply
spino13
spino13 Aug. 19 at 1:56 PM
$RDHL looks good...
0 · Reply
Dickman777
Dickman777 Aug. 18 at 3:38 PM
$RDHL give me 2
1 · Reply
therealchorris
therealchorris Aug. 18 at 1:36 PM
$RDHL …and we are down again 🤷🏼‍♂️🤪
0 · Reply
therealchorris
therealchorris Aug. 18 at 1:19 PM
$RDHL 2.3M shares outstanding is the latest number I have
0 · Reply
The_Blue_Print
The_Blue_Print Aug. 18 at 1:15 PM
$RDHL something is wrong with my numbers that I get. 11B in float??
0 · Reply
OpenOutcrier
OpenOutcrier Aug. 18 at 1:11 PM
$RDHL (+23.5% pre) RedHill receives $1.1 million in licensing payments for Talicia https://ooc.bz/l/74286
0 · Reply
therealchorris
therealchorris Aug. 18 at 1:07 PM
$RDHL Finally some good news… https://www.investing.com/news/assorted/redhill-receives-11-million-in-licensing-payments-for-talicia-432SI-4197802
0 · Reply
Genesys01
Genesys01 Aug. 15 at 2:32 PM
$RDHL RH has now 2 ways towards fulfilling Nasdaq rule: Selling something or dilution. The problem with the dilution is that nobody wants to buy this Israel cheat stock. Dror failed completely. He used SH money for just filling up his own pockets and now nobody trusts him anymore.
1 · Reply
Latest News on RDHL
RedHill Biopharma Awarded $1.8 Million in Legal Costs and Expenses by New York Supreme Court in Addition to its Prior $8.25 Million Summary Judgment Win

Aug 20, 2025, 9:00 AM EDT - 13 hours ago

RedHill Biopharma Awarded $1.8 Million in Legal Costs and Expenses by New York Supreme Court in Addition to its Prior $8.25 Million Summary Judgment Win

RedHill Received Talicia® Licensing Payments Totaling $1.1 Million

Aug 18, 2025, 9:00 AM EDT - 2 days ago

RedHill Received Talicia® Licensing Payments Totaling $1.1 Million

RedHill Receives Positive FDA Feedback on Pathway to Approval of Groundbreaking RHB-204 for Crohn's Disease

Jul 21, 2025, 9:00 AM EDT - 4 weeks ago

RedHill Receives Positive FDA Feedback on Pathway to Approval of Groundbreaking RHB-204 for Crohn's Disease

RedHill Biopharma Announces Recruitment Initiated into Expanded Phase 2 Opaganib/Darolutamide Combination Study in Advanced Prostate Cancer

Jul 1, 2025, 12:00 PM EDT - 7 weeks ago

RedHill Biopharma Announces Recruitment Initiated into Expanded Phase 2 Opaganib/Darolutamide Combination Study in Advanced Prostate Cancer

RedHill Biopharma Secures Kukbo Asset Freeze Following RedHill's $8.25 Million Plus Legal Fees New York Supreme Court Summary Judgment Win

May 13, 2025, 7:00 AM EDT - 3 months ago

RedHill Biopharma Secures Kukbo Asset Freeze Following RedHill's $8.25 Million Plus Legal Fees New York Supreme Court Summary Judgment Win

RedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology Congress

May 2, 2025, 7:00 AM EDT - 3 months ago

RedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology Congress

RedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107

Apr 28, 2025, 7:03 AM EDT - 4 months ago

RedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107

RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency

Apr 17, 2025, 4:01 PM EDT - 4 months ago

RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency

RedHill Biopharma's Positive Opaganib Weight Loss & Diabetes Data Published: Signals Potential $100B Market Disruption

Apr 16, 2025, 7:00 AM EDT - 4 months ago

RedHill Biopharma's Positive Opaganib Weight Loss & Diabetes Data Published: Signals Potential $100B Market Disruption

RedHill Biopharma Announces Full-Year 2024 Financial Results and Operational Highlights

Apr 10, 2025, 7:48 AM EDT - 4 months ago

RedHill Biopharma Announces Full-Year 2024 Financial Results and Operational Highlights

RedHill Biopharma to Submit FDA-Approved Talicia® for UK Marketing Authorisation

Mar 18, 2025, 7:00 AM EDT - 5 months ago

RedHill Biopharma to Submit FDA-Approved Talicia® for UK Marketing Authorisation

RedHill Biopharma Advances its Groundbreaking Late-Stage Crohn's Disease Program Building on Statistically Significant Positive RHB-104 Phase 3 Results

Mar 12, 2025, 7:00 AM EDT - 5 months ago

RedHill Biopharma Advances its Groundbreaking Late-Stage Crohn's Disease Program Building on Statistically Significant Positive RHB-104 Phase 3 Results

RedHill Presents Business Update at the Sachs' European Life Sciences CEO Forum

Feb 27, 2025, 7:00 AM EST - 6 months ago

RedHill Presents Business Update at the Sachs' European Life Sciences CEO Forum

RedHill Licenses RHB-102 for Commercialization Worldwide Excluding North America to Hyloris for up to $60 Million in Potential Milestone Payments Plus Royalties

Feb 25, 2025, 7:00 AM EST - 6 months ago

RedHill Licenses RHB-102 for Commercialization Worldwide Excluding North America to Hyloris for up to $60 Million in Potential Milestone Payments Plus Royalties

RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate Cancer

Feb 4, 2025, 7:00 AM EST - 7 months ago

RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate Cancer

RedHill's Talicia® Adds 8 Million Lives With Coverage by Humana®'s Part D Plan. Also, New Data Supporting Simplified Three-Times Daily Talicia Dosing Published

Jan 21, 2025, 7:00 AM EST - 7 months ago

RedHill's Talicia® Adds 8 Million Lives With Coverage by Humana®'s Part D Plan. Also, New Data Supporting Simplified Three-Times Daily Talicia Dosing Published

Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development

Dec 10, 2024, 7:00 AM EST - 9 months ago

Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development

RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court

Dec 2, 2024, 7:00 AM EST - 9 months ago

RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court

RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND

Oct 28, 2024, 7:00 AM EDT - 10 months ago

RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND

RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation Injury

Oct 22, 2024, 7:00 AM EDT - 10 months ago

RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation Injury

RedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola Treatment

Oct 14, 2024, 7:00 AM EDT - 11 months ago

RedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola Treatment

RedHill and Medi-Cal Deal Maintains Talicia® Reimbursement Without Prior Authorization for 15 Million Californians

Oct 1, 2024, 7:00 AM EDT - 11 months ago

RedHill and Medi-Cal Deal Maintains Talicia® Reimbursement Without Prior Authorization for 15 Million Californians

RedHill Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041

Sep 30, 2024, 7:00 AM EDT - 11 months ago

RedHill Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041

RedHill's Talicia® Listed as First-Line Choice for H. pylori in New American College of Gastroenterology Guidelines

Sep 9, 2024, 7:00 AM EDT - 1 year ago

RedHill's Talicia® Listed as First-Line Choice for H. pylori in New American College of Gastroenterology Guidelines

RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Sep 5, 2024, 7:00 AM EDT - 1 year ago

RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

New Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 Mortality

Sep 3, 2024, 7:00 AM EDT - 1 year ago

New Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 Mortality

RedHill Biopharma Announces First Half 2024 Business Highlights

Aug 29, 2024, 7:00 AM EDT - 1 year ago

RedHill Biopharma Announces First Half 2024 Business Highlights

RedHill's Opaganib Granted Orphan Drug Designation by the FDA for Childhood Cancer, Neuroblastoma

Aug 26, 2024, 7:00 AM EDT - 1 year ago

RedHill's Opaganib Granted Orphan Drug Designation by the FDA for Childhood Cancer, Neuroblastoma

Talicia® Launched in the United Arab Emirates

Aug 21, 2024, 7:00 AM EDT - 1 year ago

Talicia® Launched in the United Arab Emirates

Israel-Based RedHill's Investigational COVID-19 Treatment Shows Encouraging Action In Obesity And Diabetes

Aug 19, 2024, 8:56 AM EDT - 1 year ago

Israel-Based RedHill's Investigational COVID-19 Treatment Shows Encouraging Action In Obesity And Diabetes

RedHill Announces Positive Obesity and Diabetes Results with Opaganib

Aug 19, 2024, 7:00 AM EDT - 1 year ago

RedHill Announces Positive Obesity and Diabetes Results with Opaganib

RedHill Biopharma Announces Plan to Implement ADS Ratio Change

Aug 16, 2024, 7:00 AM EDT - 1 year ago

RedHill Biopharma Announces Plan to Implement ADS Ratio Change

Newly Published Positive Phase 3 Data Demonstrates 64% Increased Efficacy with RedHill's RHB-104 in Crohn's Disease

Aug 1, 2024, 7:00 AM EDT - 1 year ago

Newly Published Positive Phase 3 Data Demonstrates 64% Increased Efficacy with RedHill's RHB-104 in Crohn's Disease

RedHill Biopharma Strengthens Cash Balance, Settles Obligations and Removes Talicia® Lien

Jul 22, 2024, 7:00 AM EDT - 1 year ago

RedHill Biopharma Strengthens Cash Balance, Settles Obligations and Removes Talicia® Lien

RedHill Biopharma Terminates License Agreement for Aemcolo®

Jul 9, 2024, 8:00 AM EDT - 1 year ago

RedHill Biopharma Terminates License Agreement for Aemcolo®

RedHill Announces a New Patent Covering Opaganib in Combination with Immune Checkpoint Inhibitors, Valid Through 2040

Jun 3, 2024, 7:00 AM EDT - 1 year ago

RedHill Announces a New Patent Covering Opaganib in Combination with Immune Checkpoint Inhibitors, Valid Through 2040

RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035

May 6, 2024, 7:00 AM EDT - 1 year ago

RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035

RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study

Apr 24, 2024, 7:00 AM EDT - 1 year ago

RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study

RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights

Apr 8, 2024, 9:23 AM EDT - 1 year ago

RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights

RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price

Apr 2, 2024, 7:00 AM EDT - 1 year ago

RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price

RedHill Announces New USPTO Patent Covering Talicia® Through 2034

Mar 11, 2024, 7:00 AM EDT - 1 year ago

RedHill Announces New USPTO Patent Covering Talicia® Through 2034

RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs

Mar 5, 2024, 7:00 AM EST - 1 year ago

RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs

GILD

RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication

Feb 20, 2024, 7:00 AM EST - 1 year ago

RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication

AMGN GILD

RedHill Biopharma Announces Closing of $8 Million Registered Direct Offering

Jan 26, 2024, 12:46 PM EST - 1 year ago

RedHill Biopharma Announces Closing of $8 Million Registered Direct Offering

RedHill Biopharma Announces $8 Million Registered Direct Offering

Jan 25, 2024, 9:05 AM EST - 1 year ago

RedHill Biopharma Announces $8 Million Registered Direct Offering

RedHill Announces New USPTO Patent Grant for Talicia® for H. pylori Treatment Through 2042

Jan 25, 2024, 6:00 AM EST - 1 year ago

RedHill Announces New USPTO Patent Grant for Talicia® for H. pylori Treatment Through 2042

RedHill Biopharma shares jump as Ebola treatment shows promise

Dec 20, 2023, 9:13 AM EST - 1 year ago

RedHill Biopharma shares jump as Ebola treatment shows promise

RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola

Dec 20, 2023, 8:45 AM EST - 1 year ago

RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola

RedHill Announces New, Non-Dilutive External Funding of Entire RHB-107 COVID-19 300-Patient Phase 2 Study

Dec 4, 2023, 7:00 AM EST - 1 year ago

RedHill Announces New, Non-Dilutive External Funding of Entire RHB-107 COVID-19 300-Patient Phase 2 Study

These advisers say markets are expecting unrealistic outcomes. Here are some alternatives.

Nov 30, 2023, 9:33 AM EST - 1 year ago

These advisers say markets are expecting unrealistic outcomes. Here are some alternatives.

AAPL ABBV AMC AMZN CRM DIS GME

therealchorris
therealchorris Aug. 20 at 3:23 PM
$RDHL Looks sh’t…
0 · Reply
musti34
musti34 Aug. 20 at 1:14 PM
$RDHL RedHill Biopharma Awarded $1.8 Million in Legal Costs and Expenses by New York Supreme Court in Addition to its Prior $8.25 Million Summary Judgment Win https://www.redhillbio.com/news/news-details/2025/RedHill-Biopharma-Awarded-1-8-Million-in-Legal-Costs-and-Expenses-by-New-York-Supreme-Court-in-Addition-to-its-Prior-8-25-Million-Summary-Judgment-Win/default.aspx
0 · Reply
spino13
spino13 Aug. 19 at 1:56 PM
$RDHL looks good...
0 · Reply
Dickman777
Dickman777 Aug. 18 at 3:38 PM
$RDHL give me 2
1 · Reply
therealchorris
therealchorris Aug. 18 at 1:36 PM
$RDHL …and we are down again 🤷🏼‍♂️🤪
0 · Reply
therealchorris
therealchorris Aug. 18 at 1:19 PM
$RDHL 2.3M shares outstanding is the latest number I have
0 · Reply
The_Blue_Print
The_Blue_Print Aug. 18 at 1:15 PM
$RDHL something is wrong with my numbers that I get. 11B in float??
0 · Reply
OpenOutcrier
OpenOutcrier Aug. 18 at 1:11 PM
$RDHL (+23.5% pre) RedHill receives $1.1 million in licensing payments for Talicia https://ooc.bz/l/74286
0 · Reply
therealchorris
therealchorris Aug. 18 at 1:07 PM
$RDHL Finally some good news… https://www.investing.com/news/assorted/redhill-receives-11-million-in-licensing-payments-for-talicia-432SI-4197802
0 · Reply
Genesys01
Genesys01 Aug. 15 at 2:32 PM
$RDHL RH has now 2 ways towards fulfilling Nasdaq rule: Selling something or dilution. The problem with the dilution is that nobody wants to buy this Israel cheat stock. Dror failed completely. He used SH money for just filling up his own pockets and now nobody trusts him anymore.
1 · Reply
therealchorris
therealchorris Aug. 15 at 4:31 AM
$RDHL RedHill’s last audited figure (Dec 31, 2024) showed a stockholders’ deficit of $4.683M. That implies a swing of $2.5M − (−$4.683M) = $7.183M to reach compliance. Is this correct? Seems close to impossible.
0 · Reply
therealchorris
therealchorris Aug. 15 at 12:53 AM
$RDHL Nasdaq could have granted up to 180 days extension but only gave RedHill 60 days.
0 · Reply
Balmus
Balmus Aug. 14 at 12:42 PM
$RDHL RedHill Biopharma receives Nasdaq extension to regain compliance by October
1 · Reply
Balmus
Balmus Aug. 14 at 12:41 PM
$RDHL why clearly ?
1 · Reply
Genesys01
Genesys01 Aug. 14 at 11:27 AM
$RDHL The 6K from today shows clearly that this company is nearby bankrupt. The board pressed everything out of the investors and delivered nothing.
0 · Reply
Prometheus_Tr94
Prometheus_Tr94 Aug. 14 at 12:47 AM
$RDHL İNSANLARIN YATIRIMLARINA GÖZ KOYMANIN RESMİ
0 · Reply
Georgee23
Georgee23 Aug. 13 at 6:09 PM
$RDHL Keep an eye on her boys!
0 · Reply
Georgee23
Georgee23 Aug. 12 at 5:46 PM
$RDHL
0 · Reply
Isaaccs
Isaaccs Aug. 11 at 12:46 PM
$RDHL Given that the upamostat trial for COVID won't be able to generate significant data due to insufficient recruitment, is there anything underway at Redhill that could provide some good news in the medium term? What would be the most promising thing at this time?
0 · Reply
3PintBrain
3PintBrain Aug. 8 at 6:05 PM
$RDHL Really caved overnight, anyone have a pre-market high?
0 · Reply
Stockking24
Stockking24 Aug. 8 at 4:54 PM
$RDHL look out below suckers lol there dropping 💩 on u like white on rice…. Starting to think taken a short postion woulda been a better idea after taht last pathetic pump…..
0 · Reply
3PintBrain
3PintBrain Aug. 7 at 4:19 PM
$RDHL Bio-Scam be careful what you buy!
0 · Reply